Action potentials : e-TNS and e-ONS
CEFALY Technology has a large expertise in the techniques used to trigger electrical action potentials on cranial nerves externally (external cranial neurostimulation). Currently, it can be performed by 2 approaches :
(external Trigeminal Nerve Stimulation)
(external Occipital Nerve Stimulation)
Polarisation : t-DCS
CEFALY Technology has a large expertise in the technique used to modify the stand-by potential of the nervous cells of the cerebral cortex in order to increase or decrease the spontaneous activity of some parts of the brain. This technique is called transcranial Direct Current Stimulation (tDCS).
CEFALY Technology has acquired a deep expertise in the acquisition and analysis of biosignals. An integrated system (biofeedback) allows, for instance, to record action potentials of the face muscles in a very accurate way and to detect a simple eye blink.
The triptans are a class of molecules that stimulate the receptors of the serotonin (receptors 5-HT1B, receptors 5-HT1D and receptors 5-HT1F). This consequently reduces the dilation of the blood vessels. They are used in the treatment of the migraine crisis and of the cluster headache crisis. In the migraine, the triptans are typically used enterally (orally or nasal spray), and by subcutaneous injection in cluster headache.
The triptans are still costly and the modes of administration are not always well fitted for the patients. CEFALY Technology has started investigations on the triptans to develop new forms of administration that are cheaper and better fitted.
CEFALY Technology has started investigations to develop a simple and easy-to-use device for the treatment of the cluster headache by high flow oxygenotherapy.
CSD (cortical spreading depression) is an electrical phenomenon that develops on the cerebral cortex starting from the occipital region and that precedes the migraine crisis. Its inhibition is a new therapeutic pathway in migraine treatment. Glutamate antagonists can inhibit the CSD phenomenon. CEFALY Technology collaborates to investigations on these antagonists and thus to the development of a new therapeutic pathway.